Abstract 620P
Background
Angiogenesis is a crucial mechanism in colorectal cancer (CRC) development and progression, and anti-angiogenic drugs are a mainstay of CRC systemic treatment.
Methods
We conducted, according to Simon’s “minimax” two stage design, an open-label, single arm phase II trial to evaluate the antitumor activity of cabozantinib in pretreated metastatic CRC (mCRC) patients (pts), that progressed after at least 2 lines of prior therapy for metastatic disease. The primary endpoint was the Progression Free Survival (PFS) rate at 16 weeks; secondary endpoints include PFS, Overall Survival (OS), Response Rate (RR), Disease Control Rate, safety. Here we present the initial exploratory biomarkers analysis.
Results
From October 2019 to January 2023 a total of 33 (19 male and 14 female) pts, median age of 58 years (30-79), were treated with cabozantinib 60 mg/daily per os. A comprehensive genomic profiling by next generation sequencing (NGS) was performed with FoundationOne CDx and FoundationOne Liquid CDx (324 genes) on tumor tissue (20/33) and plasma circulating tumor DNA (ctDNA) (15/33) both in 8/33 pts. 11 out of 33 patients were free of progression at 16 weeks and were considered responders and among these the NGS analysis was available at the time of abstract submission in 10 pts. No specific genetic feature was identified in responders, only 1 patient had AXL amplification (that represents a potential target of cabozantinib). Of note MET amplification found in 2/25 pts did not correlate with response to cabozantinib. In not responding pts SMAD4 mutation as well as genetic alteration defying a “BRCAness" phenotype were most reported. RNASeq analysis is currently ongoing in 26/33 (78.8%) patient samples.
Conclusions
The ABACO study showed clinical activity of cabozantinib in a subset of refractory mCRC, to the date of the analysis no predictive markers were identified so far. Further analysis are ongoing.
Clinical trial identification
EudraCT 2019-000674-28.
Editorial acknowledgement
Legal entity responsible for the study
Department of Precision Medicine.
Funding
Ipsen partially funded.
Disclosure
F. Ciardiello: Financial Interests, Personal, Advisory Board: Roche, Merck Serono, Servier, Pierre Fabre, Pfizer; Financial Interests, Institutional, Research Grant: Merck Serono, Roche, Amgen; Financial Interests, Institutional, Local PI: Pfizer, Pierre Fabre, Servier. E. Martinelli: Financial Interests, Personal, Invited Speaker: Merck-Serono, Bayer, Merck S.p.a, ESMO; Financial Interests, Personal, Writing Engagement, Advisory board and invited speaker and travel grant: Pierre Fabre; Financial Interests, Personal, Writing Engagement, Advisory board and Invited speakers: INCYTE; Financial Interests, Personal, Writing Engagement, Advisory board and invited speaker: Servier, Roche; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Writing Engagement, Travel grant: AstraZeneca; Financial Interests, Personal, Writing Engagement, Advisory board: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10